Hanmi Pharmaceutical has licensed its poziotinib for treating several types of cancer to U.S.-based Spectrum Pharmaceuticals.
Several South Korea drug and medical-device makers can expect to be the big winners from a Constitutional Court ruling striking down the nation's law making adultery a federal crime. The law was passed in 1953 to protect women.
Various recent reports covering the near-term and long-term outlook for the pharmaceutical industry in Asia paint a positive picture with increased revenues coming from the generics and biosimilars industries along with products as specific as human insulin from China.
CrystalGenomics signed a sales and marketing deal with South Korea's Daewoong Pharmaceutical for the commercialization of Acelex (polmacoxib), granting the South Korean firm exclusive rights in country for the osteoarthritis treatment.
Almost a year after saying it would ease its policy on animal growth enhancers containing zilpaterol, the South Korean government lifted its ban on the feed additive. The move opens the door to beef imports and domestic sales of the product.
In a deal that will build on their existing mutual relationship, Bristol-Myers Squibb and Ono Pharmaceutical have formed a pact to bring immunotherapies to market in Japan, South Korea and Taiwan.
Novotech, which bills itself as Australia's largest CRO, has signed a deal with a South Korean outfit to help bolster the country's status among global drug development locales.
Bristol-Myers Squibb hooked up with South Korea's Samsung last year when it wanted someone to handle manufacturing overseas for its hot-selling melanoma drug Yervoy. But with more promising biologics in its pipeline, the New York-based drugmaker has decided to deepen its commitment.
Business Korea reported that the government has a goal for its med tech industry to export more than $12.5 billion worth of goods, hire 130,000 people and have a 3.8% global market share by 2020.
The French Big Pharma is paying SK Chemicals $23 million up front, after which both companies will invest in the project.